Immunic, inc. reports third quarter 2022 financial results and provides corporate update

– $72.8 million in cash and cash equivalents as of september 30, 2022, plus $56.4 million of net cash raised in october 2022 expected to fund immunic into the fourth quarter of 2024 – – webcast to be held today, november 3, 2022, at 8:00 am et – new york , nov. 3, 2022 /prnewswire/ -- immunic , inc.  (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended september 30, 2022 and provided a corporate update. "going forward, we are on sound financial footing, having significantly bolstered our balance sheet in october with the closing of a $60 million private placement, providing runway through multiple value inflection points into the fourth quarter of 2024," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking